Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Common Equity (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Common Equity readings, the most recent being $370.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 61.96% year-over-year to $370.1 million, compared with a TTM value of $370.1 million through Dec 2025, up 61.96%, and an annual FY2025 reading of $370.1 million, up 61.96% over the prior year.
  • Common Equity hit $370.1 million in Q4 2025 for Apellis Pharmaceuticals, down from $401.2 million in the prior quarter.
  • The five-year high for Common Equity was $462.2 million in Q1 2022, with the low at -$141.5 million in Q2 2021.
  • Median Common Equity over the past 5 years was $234.7 million (2023), compared with a mean of $229.9 million.
  • The sharpest move saw Common Equity tumbled 160.97% in 2021, then soared 794.8% in 2022.
  • Year by year, Common Equity stood at $198.7 million in 2021, then fell by 14.49% to $169.9 million in 2022, then increased by 14.51% to $194.5 million in 2023, then grew by 17.49% to $228.5 million in 2024, then soared by 61.96% to $370.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $370.1 million, $401.2 million, and $156.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.